FDA proposes new reimbursement model for antimicrobials

FDA Commissioner Scott Gottlieb said Tuesday that FDA, CMS and other agencies are discussing changing the model for how new antimicrobials are reimbursed in order to counter the obstacles inherent in commercializing these drugs.

Gottlieb said the agency is considering a licensing model for reimbursement of antimicrobial

Read the full 465 word article

User Sign In